Lyell Wealth Management LP lifted its stake in Amgen, Inc. (NASDAQ:AMGN) by 1.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 12,665 shares of the medical research company’s stock after purchasing an additional 240 shares during the quarter. Lyell Wealth Management LP’s holdings in Amgen were worth $2,078,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Alpha Omega Wealth Management LLC lifted its position in shares of Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after purchasing an additional 100 shares in the last quarter. Jackson Grant Investment Advisers Inc. lifted its position in shares of Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after purchasing an additional 4 shares in the last quarter. Nelson Roberts Investment Advisors LLC purchased a new stake in shares of Amgen in the first quarter worth approximately $121,000. Signature Estate & Investment Advisors LLC lifted its position in shares of Amgen by 13.6% in the first quarter. Signature Estate & Investment Advisors LLC now owns 794 shares of the medical research company’s stock worth $130,000 after purchasing an additional 95 shares in the last quarter. Finally, Cribstone Capital Management LLC lifted its position in shares of Amgen by 2.3% in the first quarter. Cribstone Capital Management LLC now owns 1,113 shares of the medical research company’s stock worth $182,000 after purchasing an additional 25 shares in the last quarter. 78.14% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Amgen, Inc. (AMGN) Position Increased by Lyell Wealth Management LP” was first reported by BBNS and is owned by of BBNS. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://baseballnewssource.com/markets/lyell-wealth-management-lp-buys-240-shares-of-amgen-inc-amgn/1566799.html.
A number of analysts have recently issued reports on the stock. UBS AG reissued a “neutral” rating and issued a $174.00 price target (down from $175.00) on shares of Amgen in a research report on Monday, May 22nd. Jefferies Group LLC reissued a “buy” rating and issued a $195.00 price target on shares of Amgen in a research report on Tuesday, July 11th. Royal Bank Of Canada assumed coverage on shares of Amgen in a research report on Thursday. They issued a “sector perform” rating and a $192.00 price target for the company. Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $203.00 price target on shares of Amgen in a research report on Thursday, September 7th. Finally, Leerink Swann restated a “market perform” rating and issued a $161.00 price objective on shares of Amgen in a report on Thursday, June 22nd. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $186.14.
Shares of Amgen, Inc. (AMGN) traded down 1.04% during midday trading on Friday, hitting $187.47. 5,348,992 shares of the stock traded hands. The firm’s 50 day moving average price is $175.31 and its 200 day moving average price is $169.32. The company has a market capitalization of $136.79 billion, a PE ratio of 17.08 and a beta of 1.35. Amgen, Inc. has a 12-month low of $133.64 and a 12-month high of $191.10.
Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. The business had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a return on equity of 27.67% and a net margin of 37.02%. The firm’s revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.84 EPS. Analysts expect that Amgen, Inc. will post $12.57 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Thursday, August 17th were issued a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.45%. The ex-dividend date of this dividend was Tuesday, August 15th. Amgen’s payout ratio is presently 41.93%.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with our FREE daily email newsletter.